Clinical Trials

Clinical development programs optimized for regulatory approval alone systematically fail payers, physicians, and patients. This article introduces a practical framework for designing clinical trials as integrated, stakeholder-first evidence architectures.

Drug development often succeeds function by function, then fails at the system level. Approval is only one evidentiary world. Payers, physicians, patients, and guideline committees each need different proof. If programs are designed only for endpoints, access and adoption become launch problems that should have been solved much earlier.

Summary: This article examines why mechanistic success in drug development so often fails to produce patient benefit. Drawing on a century of biological thinking — from Claude Bernard’s internal milieu to Ludwik Fleck’s thought collectives — it argues that reductionism, while essential, becomes dangerous when applied to complex adaptive systems. Three case studies (the CAST antiarrhythmic trial, beta-carotene supplementation in smokers, and sepsis cytokine targeting) illustra